Female infertility due to abnormal autoimmunity: Frequently overlooked and greatly underappreciated. Part II

Expert Review of Obstetrics and Gynecology

Volumn 2, Issue 4, 2007, Pages 465-475

  Gleicher, Norbert ^a   Weghofer, Andrea ^a   Barad, David ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

antibodies; autoimmune polyglandular syndrome; autoimmunity; infertility; miscarriage; polycystic ovarian disease; premature ovarian aging; premature ovarian failure

Indexed keywords

EID: 84962276064     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/17474108.2.4.465     Document Type: Article

References (99)

1. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocrine Rev. 18, 107–134 (1997).
2. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens and their applicability in diagnosis and disease prediction. Endocrine Rev. 23, 327–336 (2002). Erratum: 23, 579 (2002).
3. Turkington RW, Bebovitz HE. Extra-adrenal endocrine deficiencies in Addison’s disease. Am. J. Med. 43, 499–507 (1967).
4. Dal Pra C, Chen S, Furmaniak J et al. Autoantibodies to steroidogenic enzymes in patients with premature ovarian failure with and without Addison’s disease. Eur. J. Endocrinol. 148, 565–570 (2003).
5. Moran C, Potter HD, Reyna R, Boots LR, Azziz R. Prevalence of 3β-hydroxysteroid dehydrogenase-deficient nonclassical adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess. Am. J. Obstet. Gynecol. 181, 596–600 (1999).
6. Moran C, Azziz R. 21-hydroxylase-deficient nonclassical hyperplasia: the great pretender. Semin. Reprod. Med. 21, 295–300 (2003).
7. Gleicher N, Weghofer A, Barad D. Adrenal function in women with premature aging ovaries. Fertil. Steril. 86 (Suppl. 2), S401 (2006).
8. Winqvist O, Karlsson FA, Kämpe O. 21-hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet 339, 1559–1562 (1992).
9. Reiman K, Peterson P, Hyöty H et al. 3 β-hydroxysteroid dehyrogenase autoantibodies are rare in premature ovarian failure. J. Clin. Endocrinol. Metab. 85, 2324–2326 (2000).
10. Krohn K, Uibo R, Aavik E, Peterson P, Savilahti K. Identification by molecular cloning of an autoantigen associated with Addison’s disease as steroid 17α-hydoxylase. Lancet 339, 770–773 (1992).
11. Chen S, Sawicka S, Betterle C et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome. Addison’s disease and premature ovarian failure. J. Clin. Endocrinol. Metab. 81, 1871–1876 (1996).
12. Uibo R, Aavik E, Peterson P et al. Autoantibodies in cytochrome P450 enzymes P450 scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison’s disease. J. Clin. Endocrinol. Metab. 78, 323–328 (1994).
13. Moncayo-Naveda HE, Moncayo R, Benz R, Wolf R, Lauritzen C. Organ specific anibodies against ovary in patients with systemic lupus erythematosus. Am. J. Obstet. Gynecol. 160, 1227–1229 (1989).
14. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet. Gynecol. 67, 604–606 (1986).
15. Dewhurst CJ, De Koos EB, Ferreira HP. The resistant ovary syndrome. Br. J. Obstet. Gynaecol. 82, 341–345 (1975).
16. Gleicher N. Ovarian aging: is there a “norm”? Contemp. Ob./Gyn. 50, 66–75 (2005).
17. Nikolaou D, Templeton A. Early ovarian ageing. A hypothesis. Detection and clinical relevance. Hum. Reprod. 18, 1137–1139 (2003).
18. Levran D, Ben-Shalom I, Pariente C, Dor J, Mashiach S, Weissman A. Familial partial 17,20 desmolase and 17 α hydroxylase deficiency presenting as infertility. J. Assist. Reprod. Genet. 20, 21–28 (2003).
19. Taniyama M, Tanabe M, Saito H, Ban Y, Natawa H, Yanase T. Subtle 17α-hydroxylase/17,20 lyase deficiency with homozgeous Y201N mutation in an infertile woman. J. Clin. Endocrin. Metab. 90, 2508–2511 (2005).
20. Pellicer A, Miro F, Sampaio M, Gomez E, Bonilla-Musoles FM. In vitro fertilization as a diagnostic and therapeutic tool in a patient with partial 17,20 desmolase deficiency. Fertil. Steril. 55, 970–975 (1991).
21. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum. Reprod. 21, 2845–2849 (2006).
22. Van Vollenhofen RF. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin. Pharmacother. 3, 23–31 (2003).
23. Doldi N, Belvisi DN, Fusi BM, Ferrari A. Premature ovarian failure: steroid synthesis and autoimmunity. Gynecol. Endocrinol. 12, 23–28 (1998).
24. Welt CK, Falorni A, Taylor AE, Martin KA, Hall JE. Selective theca cell dysfunction in autoimmune oophoritis results in multifollicular development, decreased estradiol, and elevated inhibin B levels. J. Clin. Endocrin. Metab. 90, 3069–3076 (2005).
25. Siegel SF, Finegold DN, Lanes R, Lee PA. ACTH stimulation tests and plasma dehyroepiandrosterone sulfate levels in women with hirsutism. N. Engl. J. Med. 323, 849–854 (1990).
26. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81, 19–25 (2004).
27. Van Gelderen CJ, Gomes dos Santos MI. Polycystic ovarian syndrome. Evidence for an autoimmune mechanism in some cases. J. Reprod. Med. 38, 381–386 (1993).
28. Lonsdale RN, Roberts PF, Trowell JE. Autoimmune oophoritis associated with polycystic ovaries. Histopathology 19, 77–81 (1991).
29. Janssen OE, Mehlmauer N, Hahn S, Öffner H, Gärtner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur. J. Endocrin. 150, 363–369 (2004).
30. Fenichel P, Gobert B, Carre Y, Barbarino-Monnier P, Hieronimus S. Polycystic ovary syndrome in autoimmune diseases. Lancet 353, 2210 (1999).
31. Irvine WJ, Barnes EW. Addison’s disease, ovarian failure and hypopara-thyroidism. Clin. Endocrinol. Metab. 4, 379–434 (1975).
32. Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison’s disease. J. Autoimmun. 8, 121–130 (1995).
33. Söderbergh A, Winqvist O, Nordheim I et al. Adrenal autoantibodies and organ-specific autoimmunity in Addison disease. Clin. Endocrinol. (Oxf.) 45, 453–460 (1996).
34. Bachega TASS, Billerbeck AEC, Marcondes JAM, Madureira G, Amhold IJP, Mendonca BB. Influence of different genotype on 17-hydroxyprogesterone levels in patients with nonclassic congenital adrenal hyperplasia due to 21-hyroxylase deficiency. Clin. Endocrinol. 52, 601–607 (2000).
35. Deneux C, Taerdy V, Dib A et al. Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21 hydroxylase deficiency. J. Clin. Endocrin. Metab. 86, 207–213 (2001).
36. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. Br. Med. J. 328, 750–754 (2004).
37. Daneman D. Type 1 diabetes. Lancet 367, 847–858 (2006).
38. Redondo MJ, Fain PR, Eisenbarth GS. Genetics of Type 1A diabetes. Recent Progr. Horm. Res. 56, 69089 (2001).
39. Robles DT, Eisenbarth GS. Type 1A diabetes induced by infection and immunization. J. Autoimmun. 16, 355–362 (2001).
40. Lammi N, Karvonen M, Tuomilehto J. Do microbes have a causal role in type 1 diabetes? Med. Sci. Monit. 11, RA63 –RA69 (2005).
41. Vaarala O, Knip M, Paronen J et al. Cow’s milk formula feeding induces primary immunization to insulin in infants at genetic risk for Type 1 diabetes. Diabetes 48, 1389–1394 (1999).
42. Norris JM, Barriga K, Klingensmith G et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 290, 1713–1720 (2003).
43. Helgason T, Jonasson ME. Evidence for food additive as a cause of ketosis-prone diabetes. Lancet 318, 716–720 (1981).
44. Akerblom HK, Vaarala O, Hyoty H, Ilonen J, Knip M. Environmental factors in the etiology of Type 1 diabetes. Am. J. Med. Genet. 115, 18–29 (2002).
45. Barker JM, Yu J, Yu L et al. Autoantibody “subspecificity” in Type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care 28, 850–855 (2005).
46. Kordonouri O, Hartmann R, Deiss D, Wilms M, Gruters-Kieslich A. Natural course of autoimmune thyroiditis in Type 1 diabetes: association with gender, age diabetes duration, and puberty. Arch. Dis. Child 90, 411–414 (2005).
47. Skovbjerg H, Tarnow L, Locht H, Parving HH. The prevalence of celiac disease in adult Danish patients with Type 1 diabetes with and without nephropathy. Diabetologia 48, 1416–1417 (2005).
48. Dahlquist G, Mustonen L. Analysis of 20 years of prospective registration of childhood onset diabetes time trends and birth cohort effects. Swedish Childhood Study Group. Acta Paediatr. 89, 1231–1237 (2000).
49. Kjaer K, Hagen C, Sando SH, Eshoj O. Infertility and pregnancy outcome in an unselected group of women with insulin-dependent diabetes mellitus. Am. J. Obstet. Gynecol. 166, 1412–1418 (1992).
50. Goldman JA, Dicker D, Feldberg D, Yeshaya A, Samuel N, Karp M. Pregnancy outcome in patients with insulin-dependent diabetes mellitus with preconceptional diabetic control: a comparative study. Am. J. Obstet. Gynecol. 155, 293–297 (1986).
51. Gleicher N. Modern obstetrical and infertility care may increase the prevalence of disease: an evolutionary concept. Fertil. Steril. 79, 249–252 (2003).
52. Stagnaro-Green A, Roman SH, Cohen RH, El-Harazy E, Wallerstein S, Davies TF. A prospective study of lymphocyte-initiated immuno-suppression in normal pregnancy: evidence of T-cell etiology for postpartum thyroid dysfunction. J. Clin. Endocrinol. Metab. 74, 645–653 (1992).
53. Idris I, O’Malley BP. Thyrotoxicosis in Down’s and Turner’s syndromes: the likelihood of Hashimoto’s thyroiditis as the underlying aetiology. Int. J. Clin. Practice 54, 272–273 (2000).
54. Boehm BO, Kuhnl P, Loliger C et al. HLA-DR3 and HLA-DR5 confer risk of autoantibody positivity against the thyroperoxidase (mic-TPO) antigen in healthy blood donors. Clin. Invest. 71, 221–225 (1993).
55. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocrine Rev. 17, 369–384 (1996).
56. Kita M, Goulis DG, Avramides A. Post partum thyroiditis in a Mediterranean population. J. Endocrinol. Invest. 25, 513–519 (2002).
57. Asukai K, Uemura T, Minaguchi H. Occult hyperprolactemia in infertile women. Fertil. Steril. 60, 423–427 (1993).
58. Wakim AN, Polizotto SL, Burholt DR. Augmentation by thyroxine of human granulose cell gonadotrophin-induced steroidogenesis. Hum. Reprod. 10, 2845–2848 (1995).
59. Bussen S, Steck T, Dietl J. Increased prevalence of thyroid antibodies in euthyroid women with a history of recurrent in-vitro fertilization failure. Hum. Reprod. 15, 545–548 (2000).
60. Pratt D, Novotny M, Kaberlein G, Dudkiewicz A, Gleicher N. Antithyroid antibodies and the association with non-organ-specific antibodies in recurrent pregnancy loss. Am. J. Obstet. Gynecol. 168, 837–841 (1993).
61. Stagnaro-Green A, Roman SH, Cobin RH, el Harazy E, Alvarez-Marfany M, Davies TF. Detection of at risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAMA 264, 1422–1425 (1990).
62. Singh A, Dantas ZC, Stone SC, Asch RH. Presence of thyroid antibodies in early reproductive failure: biochemical versus clinical pregnancies. Fertil. Steril. 63, 277–281 (1995).
63. Neufeld M, Blizzard RM. Polyglandular autoimmune disease. In: Autoimmune Aspects of Endocrine Disorders. Pinchera A, Doniach D, Fenzi DF, Baschieri L (Eds). Academic Press, London, UK 357–365 (1980).
64. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N. Engl. J. Med. 350, 2068–2079 (2004).
65. Claude H, Gourgerot H. Insuffisance pluriglandulaire endocrinienne. J. Physiol. Pathol. Gen. 10, 469–480 (1908).
66. Kamradt T, Avrion Mitchison N. Tolerance and autoimmunity. N. Engl. J. Med. 344, 655–664 (2001).
67. Tadmor B, Putterman C, Naparstek Y. Embryonal germ-layer antigens: target for autoimmunity. Lancet 339, 975–978 (1992).
68. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy–candidiasis–ecto-dermal dystrophy (APECED) in a series of 68 patients. N. Engl. J. Med. 322, 1829–1836 (1990).
69. Perheentupa J. APS-I/APECED: the clinical disease and therapy. Endocrinol. Metab. Clin. North Am. 31, 295–320 (2002).
70. Doniach D, Bottazzo GF. Polyendocrine autoimmunity. In: Clinical Immunology Update. Franklin EC (Ed.). Elsevier-North Holland, Amsterdam, The Netherlands 95–121 (1981).
71. Zlotogara J, Shapiro MS. Polyglandular autoimmune syndrome type I among Iranian Jews. J. Med. Genet. 29, 824–826 (1992).
72. Clemente MG, Obermyer-Straub P, Meloni A et al. Cytochrome P450 IA2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J. Clin. Endocrinol. Metab. 82, 1353–1361 (1997).
73. Perheentupa J, Miettinen A. Type 1 autoimmune polyglandular disease. Ann. Med. Interne (Paris) 150, 313–325 (1999).
74. Peterson S, Nagamine K, Scott H et al. APECED: a monogenetic autoimmune disease providing new clues to self-tolerance. Immunol. Today 19, 284–286 (1998).
75. Rose NR. Is idiopathic hypoparathyroidism an autoimmune disease? J. Clin. Invest. 97, 899–900 (1996).
76. Kumar PG, Laloraya M, She JX. Population genetics and functions of the autoimmune regulator (AIRE). Endocrinol. Metab. Clin. North Am. 31, 321–338 (2002).
77. Schatz DA, Winter WE. Autoimmune polyglandular syndrome. II. Clinical syndrome and treatment. Endocrinol. Metab. Clin. North Am. 31, 339–352 (2002).
78. Papadopoulos KI, Hallengreen B. Polyglandular autoimmune syndrome type II in patients with idiopathic Addison’s disease. Acta Endocrinol. (Copenh.) 122, 472–478 (1990).
79. Eisenbarth GS, Wilson PN, Ward F, Buckley C, Lebovitz H. The polyglandular failure syndrome: disease inheritance, HLA-type and immune function studies in patients and families. Ann. Intern. Med. 91, 528–533 (1979).
80. Klein J, Sato A. The HLA system. First of two parts. N. Engl. J. Med. 343, 702–709 (2000).
81. Klein J, Sato A. The HLA system. Second of two parts. N. Engl. J. Med. 343, 782–786 (2000).
82. Muir A, She JX. Advanced in the genetics and immunology of autoimmune polyglandular syndrome II/III and their clinical applications. Ann. Med. Intern. 150, 301–312 (1999).
83. Cosman F, Post KD, Holub DA, Wardlaw SL. Lymphocytic hypophysitis. Report of 3 new cases and review of the literature. Medicine 68, 240–246 (1989).
84. Crock P. Cytosolic autoantigens in lymphocytic hypophysitis. J. Clin. Endo. Metabol. 83, 609–618 (1998).
85. Crock P, Salvi M, Miller A, Wall J, Guyda H. Detection of anti-pituitary autoantibodies by immunoblotting. J. Immunol. Methods 162, 31–40 (1993).
86. Strömberg S, Crock P, Lernmark A, Hulting A-L. Pituitary autoantibodies in patients with hypopituitarism and their relatives. J. Endocrinol. 157, 475–480 (1998).
87. Tanaka S, Tatsumi KI, Takano T et al. Anti-α-enolase antibodies in pituitary disease. Endocr. J. 50, 697–702 (2003).
88. Feigenbaum SL, Martin MC, Wilson CB, Jaffe RB. Lymphocytic adenohypophysitis: a pituitary mass lesion occurring in pregnancy. Proposal for medical treatment. Am. J. Obstet. Gynecol. 164, 1549–1555 (1991).
89. Asa SL, Bilbao JM, Kovacs K, Josse RG, Kreines K. Lymphocytic hypophysitis of pregnancy resulting in hypopituitarism: a distinct clinicopathologic entity. Ann. Intern. Med. 95, 166–171 (1981).
90. Goudie RB, Pinkerton PH. Anterior hypophysitis and Hashimoto’s disease in young women. J. Pathol. Bacteriol. 41, 584–585 (1962).
91. Yoon JW, Choi DS, Liang HC et al. Induction of organ-specific autoimmune disease, lymphocytic hypophysitis, in hamsters by recombinant rubella virus glycoprotein and prevention of disease by neonatal thymectomy. J. Virol. 66, 1210–1214 (1992).
92. Pivonello R, De Bellis A, Faggiano A et al. Central diabetes insipidus and autoimmunity: relationship between occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in large cohort of patients with central diabetes insipidus of known and unknown etiology. Clin. Endo. Metabol. 88, 1629–1636 (2003).
93. Gleicher N, Barad D. An evolutionary concept of polycystic ovarian disease: does evolution favour reproductive success over survival? Reprod. Biomed. Online 5, 587–589 (2006).
94. Wu J. Could evidence-based medicine be a danger to progress? Lancet 366, 122 (2005).
95. Poppe K, Velkeniers B. Thyroid disorders in infertile women. Ann. Endocrinol. (Paris) 64, 45–50 (2003).
96. Lyons R, Narain S, Nichols C, Satoh M, Reeves WH. Effective use of autoantibody tests in the diagnosis of systemic autoimmune diseases. Ann. NY Acad. Sci. 1050, 217–228 (2005).
97. Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann. NY Acad. Sci. 1069, 322–345 (2006).
98. Uwaifo GI, Merke DP. C-17 hydroxylase deficiency. Ememedicine www.ememedicine.com.med/topic380.htm
99. Ovarian failure. www.medceu.com/course-no-test.cfm?cid=926